Anzeige
Mehr »
Donnerstag, 07.08.2025 - Börsentäglich über 12.000 News
Große CEO-Enthüllung: Analysten sehen +56% Potenzial
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QJRU | ISIN: US30233G2093 | Ticker-Symbol: PV3B
Tradegate
06.08.25 | 19:44
8,796 Euro
-3,04 % -0,276
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
EYEPOINT PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
EYEPOINT PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
8,9929,26210:24
8,9929,26210:24

Aktuelle News zur EYEPOINT PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiEyePoint signals 2026 LUGANO Phase III data and NDA filing for DURAVYU amid accelerated trial enrollment4
EYEPOINT PHARMACEUTICALS Aktie jetzt für 0€ handeln
MiEyePoint Pharmaceuticals, Inc.: EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments98- Completed Phase 3 enrollment for DURAVYU in wet AMD with over 800 patients enrolled and randomized - - LUGANO and LUCIA trials each rapidly enrolled in seven months underscoring strong physician...
► Artikel lesen
MiEyePoint Pharmaceuticals, Inc. - 8-K, Current Report-
DiEyePoint Pharmaceuticals Q2 2025 Earnings Preview20
30.07.EyePoint Pharmaceuticals, Inc.: EyePoint to Report Second Quarter 2025 Financial Results on August 6, 20256
29.07.EyePoint Pharmaceuticals, Inc.: EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU in Wet Age-Related Macular Degeneration1.488- LUCIA pivotal Phase 3 trial enrolled and randomized over 400 patients in seven months, demonstrating continued strong enthusiasm for the DURAVYU pivotal program across the global retinal community...
► Artikel lesen
29.07.EyePoint Pharmaceuticals, Inc. - 8-K, Current Report1
16.07.EyePoint Pharmaceuticals, Inc.: EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)128WATERTOWN, Mass., July 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients...
► Artikel lesen
20.06.EyePoint Pharmaceuticals, Inc. - 8-K, Current Report9
17.06.Forecasting The Future: 4 Analyst Projections For EyePoint Pharmaceuticals10
16.06.EyePoint Pharmaceuticals, Inc.: EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)267WATERTOWN, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients...
► Artikel lesen
30.05.EyePoint advances with Duravyu Phase III trial8
30.05.H.C. Wainwright maintains Buy on EyePoint with $22 target4
29.05.Analyst Expectations For EyePoint Pharmaceuticals' Future1
27.05.JPMorgan maintains EyePoint stock Overweight with $26 target9
27.05.JPMorgan behält Overweight-Rating für EyePoint-Aktie mit Kursziel von 26 US-Dollar bei12
27.05.EyePoint auf dem Stifel Forum: Strategische Fortschritte in der Augenheilkunde16
27.05.EyePoint Pharmaceuticals, Inc. - 8-K, Current Report1
27.05.EyePoint Pharmaceuticals, Inc.: EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU for Treatment of Wet Age-Related Macular Degeneration249- Over 400 patients enrolled and randomized over a seven-month period, driven by strong physician and patient interest - - LUCIA pivotal Phase 3 trial continues rapid enrollment pace with 60% of...
► Artikel lesen
16.05.EyePoint Pharmaceuticals, Inc.: EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)352WATERTOWN, Mass., May 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients...
► Artikel lesen
Weiter >>
46 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1